Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rVWF in Elective Surgery for Severe Von Willebrand Disease
NCT02283268Phase 3Completed
- Sponsor
- Takeda
- Start
- Apr 2015
- Primary completion
- Jul 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 13
01
Overview
A Phase 3 trial of vonicog alfa in von Willebrand disease (VWD), sponsored by Takeda. Started Apr 2015; status: completed.
02
Drugs
vonicog alfa
03
Conditions
von Willebrand disease (VWD)
Beyond the preview
Go deeper on NCT02283268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02283268.